10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

Form 10-Q

(Mark One)

[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2015

[  ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 5(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ______________________________ to ______________________________

Commission File Number 33-55254-41

BIOETHICS, LTD.
(Exact name of registrant as specified in charter)
NEVADA	87-0485312
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)
1661 Lakeview Circle, Ogden, Utah	84403
(Address of principal executive offices)	(Zip Code)
(801) 399-3632
(Issuer’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  

Yes [X]    No [  ]

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).  

Yes [X]    No [  ]

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company.  See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer

[  ]

Accelerated filer

[  ]

Non-accelerated filer

[  ]

Smaller reporting company

[X]

Indicate by check mark whether the issuer is a shell company (as defined in rule 12b-2 of the Exchange Act).

Yes [X]    No [  ]

As of November 9, 2015, the issuer had outstanding 116,000,000 shares of common stock, par value $0.001. 

1

BIOETHICS, LTD.

FORM 10-Q

FOR THE QUARTER ENDED SEPTEMBER 30, 2015

INDEX

PART I   Financial Information

Item 1.

Financial Statements (Unaudited)

3

Item 2.  Management’s Discussion and Analysis of Financial Condition

and Results of Operations

 9

Item 3.  Quantitative and Qualitative Disclosures About Market Risk

 10

Item 4.  Controls and Procedures

 11

PART II Other Information

Item 1.  Legal Proceedings

11

Item 1A.  Risk Factors

11

Item 2.  Unregistered Sales of Equity Securities and Use of Proceeds

11

Item 3.  Defaults Upon Senior Securities

12

Item 4.  Mine Safety Disclosures

12

Item 5.  Other Information

12

Item 6.  Exhibits

12

SIGNATURES

14

1

PART I – FINANCIAL INFORMATION

BIOETHICS, LTD.

CONTENTS

PAGE



Unaudited Condensed Balance Sheets,

September 30, 2015 and December 31, 2014

4



Unaudited Condensed Statements of Operations,

For the three and nine months ending September 30, 2015 and 2014 (restated)

5



Unaudited Condensed Statements of Cash Flows,

For the nine months ended September 30, 2015 and 2014 (restated)

                         6



Notes to Unaudited Condensed Financial Statements for the three and nine months

ended September 30, 2015 and 2014 (restated)

7

BIOETHICS, LTD.
Condensed Balance Sheets
(Unaudited)
ASSETS
			September 30,	December 31,
			2015	2014
CURRENT ASSETS
	Cash and cash equivalents		$         92,879	$         11,634
	Prepaid expenses		1,875	7,500
		Total Current Assets	94,754	19,134
		TOTAL ASSETS	$         94,754	$         19,134
LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)
CURRENT LIABILITIES
	Accounts payable		$           6,128	$                   -
	Accrued interest		1,836	-
	Accrued interest - related party		1,500	-
	Note payable - related party		25,000	25,000
	Convertible note payable (net of discount of $83,333 and $-0-,
	respectively)		16,667	-
		Total Current Liabilities	51,131	25,000
		TOTAL LIABILITIES	51,131	25,000
STOCKHOLDERS' EQUITY (DEFICIT)
	Preferred stock, $0.01 par value; 25,000,000 shares
	authorized, -0- shares issued and outstanding		-	-
	Common stock, $0.001 par value; 150,000,000 shares
	authorized, 116,000,000 shares issued and outstanding		116,000	116,000
	Additional paid-in capital		385,414	285,414
	Accumulated deficit		(457,791)	(407,280)
		Total Stockholders' Equity (Deficit)	43,623	(5,866)
		TOTAL LIABILITIES AND STOCKHOLDERS'  EQUITY (DEFICIT)	$         94,754	$         19,134
The accompanying notes are an integral part of these unaudited condensed financial statements.

BIOETHICS, LTD.
Condensed Statements of Operations
(Unaudited)
			For the Three Months Ended		For the Nine Months Ended
			September 30,		September 30,
			2015	2014	2015	2014
				(Restated)		(Restated)
NET REVENUES			$                   -	$                   -	$                   -	$                   -
OPERATING EXPENSES
	General and administrative		13,343	995	29,758	14,072
		Total Operating Expenses	13,343	995	29,758	14,072
LOSS FROM OPERATIONS			(13,343)	(995)	(29,758)	(14,072)
OTHER INCOME (EXPENSES)
	Loss on extinguishment of debt		-	(187,500)	-	(187,500)
	Interest expense		(19,253)	-	(20,753)	(2,123)
		Total Other Income (Expenses)	(19,253)	(187,500)	(20,753)	(189,623)
NET LOSS BEFORE INCOME TAXES			(32,596)	(188,495)	(50,511)	(203,695)
PROVISION FOR INCOME TAXES			-	-	-	-
NET LOSS			$        (32,596)	$      (188,495)	$        (50,511)	$      (203,695)
BASIC AND DILUTED LOSS PER SHARE			$            (0.00)	$            (0.00)	$            (0.00)	$            (0.00)
WEIGHTED AVERAGE NUMBER OF
SHARES OUTSTANDING			116,000,000	116,000,000	116,000,000	81,000,000
The accompanying notes are an integral part of these unaudited condensed financial statements.

BIOETHICS, LTD.
Statements of Cash Flows
(Unaudited)
			For the Nine Months Ended
			September 30,
			2015	2014
				(Restated)
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss			$        (50,511)	$      (203,695)
Adjustments to reconcile net loss to net cash
used by operating activities:
		Amortization of debt discounts	16,667	-
		Loss on extinguishment of debt	-	187,500
Changes in operating assets and liabilities:
		Prepaid expenses	5,625	(380)
		Accounts payable	6,128	(2,161)
		Accrued interest	1,836	-
		Accrued interest - related party	1,500	2,123
		Net Cash Used by Operating Activities	(18,755)	(16,613)
CASH FLOWS FROM INVESTING ACTIVITIES			-	-
CASH FLOWS FROM FINANCING ACTIVITIES
	Capital contribution		-	5,137
	Proceeds from notes payable		100,000	11,175
		Net Cash Provided by Financing Activities	100,000	16,312
INCREASE (DECREASE) IN CASH
AND CASH EQUIVALENTS			81,245	(301)
CASH AND CASH EQUIVALENTS AT
BEGINNING OF PERIOD			11,634	359
CASH AND CASH EQUIVALENTS AT
END OF PERIOD			$         92,879	$           58
SUPPLEMENTAL DISCLOSURES:
	Cash paid for interest		$              750	$                   -
	Cash paid for income taxes		$                   -	$                   -
	Non-cash financing activity:
		Conversion of unsecured promissory notes payable	$                   -	$       105,000
The accompanying notes are an integral part of these unaudited condensed financial statements.

BIOETHICS, LTD.

NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS

THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2015 and 2014 (Restated)

NOTE 1  SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Organization - Bioethics, Ltd. (“the Company”) was organized under the laws of the State of Nevada on July 26, 1990.  The Company was organized to provide a vehicle for participating in potentially profitable business ventures which may become available through the personal contacts of, and at the complete discretion of, the Company’s officers and directors.  The Company has, at the present time, not paid any dividends and any dividends that may be paid in the future will depend upon the financial requirements of the Company and other relevant factors.

Condensed Financial Statements - The accompanying financial statements have been prepared by the Company without audit.  In the opinion of management, all adjustments (which include only normal recurring adjustments) necessary to present fairly the financial position, results of operations and cash flows at September 30, 2015 and 2014 (restated) and for the three and nine months ended September 30, 2015 and 2014 (restated) have been made.

Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted.  It is suggested that these condensed financial statements be read in conjunction with the financial statements and notes thereto included in the Company’s December 31, 2014 audited financial statements.  The results of operations for the periods ended September 30, 2015 and 2014 (restated) are not necessarily indicative of the operating results for the full year.

NOTE 2 - STOCKHOLDERS’ EQUITY (DEFICIT)

Common Stock - In July 1990, in connection with its organization, the Company issued 1,000,000 shares of its previously authorized but unissued common stock.  Total proceeds from the sale of stock amounted to $1,000 (or $.001 per share).

In May 1998, the Company issued 10,000,000 shares of its previously authorized but unissued common stock.  Total proceeds from the sale of stock amounted to $40,000 (or $.004 per share).  The issuance of common stock resulted in a change in control of the Company.

In June 2014, the Company issued 105,000,000 shares of its previously authorized but unissued common stock for satisfaction of debts in the amount of $105,000 (see NOTE 3). The best-efforts Enterprise value of the shares issued was determined by management to be $292,500 (or $.003 per share). The excess of the fair value of the stock issued over the value of the debt settled of $187,500 has been recorded as a loss on extinguishment of debt.  The transaction resulted in a change in control of the Company, as well as a restatement of the September 30, 2014 comparative financial statements as illustrated in NOTE 9.

As discussed in NOTE 4, the Company recorded a debt discount totaling $100,000 in connection with a convertible note payable issued during the three months ended September 30, 2015.  This resulted in a corresponding increase of $100,000 to additional paid-in capital.

NOTE 3  RELATED PARTY TRANSACTIONS

Management Compensation - During the three and nine months ended September 30, 2015 and 2014, the Company did not pay any compensation to its officers and directors.

Office Space - The Company has not had a need to rent office space.  An officer/shareholder of the Company is allowing the Company to use his home as a mailing address, as needed, at no expense to the Company.

Notes Payable - Between January 2010 and March 2014, the Company borrowed $91,000 from a minority stockholder of the Company pursuant to unsecured promissory notes, which were due on demand and accrued interest at 6% per annum. In June 2014, the principal amount of $91,000, along with accrued interest of $14,000, was purchased by the Company’s then-sole officer and director and settled via the issuance of 105,000,000 shares of common stock of the Company.  This resulted in a change of control, as the former officer and director now owns 90.5% of the Company’s issued and outstanding stock.  In December 2014, the Company borrowed $25,000 from this majority shareholder pursuant to an unsecured promissory note, which is due on demand and accrues interest at

BIOETHICS, LTD.

NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS

THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2015 and 2014 (Restated)

12% per annum, or $750 per quarter.  The note has accrued $2,250 in interest since its inception, of which $1,500 remains payable at September 30, 2015.

NOTE 4 - CONVERTIBLE NOTE PAYABLE

On July 25, 2015, the Company issued a promissory note in the original principal amount of $100,000 to a lender. The Note is due on demand at any time after July 31, 2016 and carries an interest rate of 10% per annum. The Note shall be due and payable in full unless converted partially or in its entirety upon the election of the lender into fully paid and non-assessable shares of common stock of the Company at a conversion rate of $0.25 per share.  The Company recognized a beneficial conversion feature and recorded a debt discount in the amount of $100,000.  This amount is being amortized over the life of the promissory note.  During the three and nine months ended September 30, 2015, the company recorded $16,667 as amortization of debt discount on the condensed statements of operations, resulting in an unamortized debt discount of $83,333 and net convertible note balance of $16,667 at September 30, 2015.  Accrued interest and interest expense as of and for the nine months ended September 30, 2015 totaled $1,836.

NOTE 5 - GOING CONCERN

The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America, which contemplate continuation of the Company as a going concern.  However, the Company has incurred losses since its inception and has no on-going operations.  These factors raise substantial doubt about the ability of the Company to continue as a going concern.  In this regard, management is proposing to raise any necessary additional funds not provided by operations through loans, additional sales of its common stock or through a possible business combination.  There is no assurance that the Company will be successful in raising this additional capital or in achieving profitable operations.  The financial statements do not include any adjustments that might result from the outcome of these uncertainties.

NOTE 6 - LOSS PER SHARE

The following data show the amounts used in computing loss per share:

	For the	For the	For the	For the
	Three Months	Three Months	Nine Months	Nine Months
	Ended	Ended	Ended	Ended
	September 30,	September 30,	September 30,	September 30,
	2015	2014	2015	2014
		(Restated)		(Restated)
Loss from continuing operations
applicable to common
stockholders (numerator)	$  (32,596)	$ (188,495)	$(50,511)	(203,695)
Weighted average number of
common shares outstanding
used in loss per share calculation
during the period (denominator)	116,000,000	116,000,000	116,000,000	81,000,000

Dilutive loss per share was not presented; as the Company had no common share equivalents for all periods presented that would affect the computation of diluted loss per share. In addition, the Company has experienced continuing losses, so inclusion of any common share equivalents would result in an anti-dilutive effect.

NOTE 7 – SUBSEQUENT EVENTS

The Company has evaluated subsequent events from the balance sheet date through the date the financial statements were issued and determined there are no additional events to disclose.

BIOETHICS, LTD.

NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS

THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2015 and 2014 (Restated)

Note 8 – DEVELOPMENT STAGE OPERATIONS

On June 10, 2014, the Financial Accounting Standards Board ("FASB") issued update ASU 2014-10, “Development Stage Entities” (Topic 915).   Amongst other things, the amendments in this update removed the definition of development stage entity from Topic 915, thereby removing the distinction between development stage entities and other reporting entities from US GAAP.  In addition, the amendments eliminate the requirements for development stage entities to (1) present inception-to-date information on the statements of income, cash flows and shareholders’ equity, (2) label the financial statements as those of a development stage entity;  (3) disclose a description of the development stage activities in which the entity is engaged, and (4) disclose in the first year in which the entity is no longer a development stage entity that in prior years it had been in the development stage.  The amendments are effective for annual reporting periods beginning after December 31, 2014 and interim reporting periods beginning after December 15, 2015.  As such, the Company has not labeled the financial statements as those of a development stage entity and has not presented inception-to-date information on the respective financial statements

NOTE 9 – RESTATEMENT

As detailed in NOTE 2, in June 2014 the Company issued 105,000,000 shares of common stock valued at $292,500 for satisfaction of debts in the amount of $105,000.  The loss on extinguishment of debt resulting from the excess of the fair value of the stock issued over the debt settled of $187,500 (with offsetting entry to additional paid-in capital) was not considered at the time of the transaction, and was not recorded until the December 31, 2014 audit.  Thus, the applicable unaudited September 30, 2014 items have been restated in the accompanying financial statements and footnotes as follows:

	At September 30, 2014
	Amount as
	Originally		Restated
Account	Filed	Adjustment	Amount
Additional paid-in capital	$     97,913	$    187,500	$   285,413
Accumulated deficit	(215,284)	(187,500)	(402,784)
	3 Months Ended September 30, 2014			9 Months Ended September 30, 2014
	Amount as			Amount as
	Originally		Restated	Originally		Restated
Account	Filed	Adjustment	Amount	Filed	Adjustment	Amount
Loss on extinguishment of debt	-	(187,500)	(187,500)	-	(187,500)	(187,500)
Total other income (expense)	-	(187,500)	(187,500)	(2,123)	(187,500)	(189,623)
Net loss	(995)	(187,500)	(188,495)	(16,195)	(187,500)	(203,695)
Net loss per share	$      (0.00)	$       (0.00)	$      (0.00)	$    (0.00)	$       (0.00)	$   (0.00)

Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations.

You should read the following discussion in conjunction with our financial statements, which are included elsewhere in this report.  The following information contains forward-looking statements. (See “Forward-Looking Statements” below and “Risk Factors.”)

FORWARD-LOOKING STATEMENTS

This report contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995.  These statements reflect the Company’s views with respect to future events based upon information available to it at this time.  These forward-looking statements are subject to certain uncertainties and other factors that could cause actual results to differ materially from these statements.  These uncertainties and other factors include, but are not limited to the risk factors described herein under the caption “Risk Factors.”  The words “anticipates,” “believes,” “estimates,” “expects,” “plans,” “projects,” “targets” and similar expressions identify forward-looking statements.  Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date the statement was made.  The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, changes in assumptions, future events or otherwise.

General

The Company is a shell company that conducts no active business operations and is seeking business opportunities for acquisition or participation by the Company.

The Report of Independent Registered Public Accounting Firm on the Company’s 2014 audited financial statements addresses an uncertainty about the Company’s ability to continue as a going concern, indicating that the Company has incurred losses since its inception and has no on-going operations.  The report further indicates that these factors raise substantial doubt about the Company’s ability to continue as a going concern.  At September 30, 2015, the Company had a working capital deficit of $43,623 and a deficit since inception of $457,791. The Company incurred net losses of $50,511 and $203,695 for the nine months ended September 30, 2015 and 2014, respectively.  The Company has not entered into any agreements or arrangements for the provision of additional debt or equity financing and there can be no assurance that it will be able to obtain the additional debt or equity capital required to continue its operations.  

The Fiscal Quarter ended September 30, 2015 Compared to the Fiscal Quarter ended September 30, 2014

The Company did not conduct any operations during the three month periods ended September 30, 2015 or 2014, and had no assets other than cash and prepaid expenses.  At September 30, 2015, the Company had cash in the amount of $92,879 as compared to cash at December 31, 2014 in the amount of $11,634.  The increase in cash is mainly the result of the proceeds from a convertible promissory note payable in the amount of $100,000 received during the quarter ended September 30, 2015.  At September 30, 2015, the Company had total current liabilities of $51,131, consisting of accounts payable of $6,128, interest payable to shareholder of $1,500, interest on convertible notes payable of $1,836, notes payable to a stockholder of $25,000, and convertible notes payable of $16,667 (net of discount of $83,333).  The increase in current liabilities mainly represents accrual of general corporate bills received and the new promissory note payable in the amount of $100,000.The Company had a working capital deficit of $43,623 at September 30, 2015 as compared to a working capital deficit of $5,866 at December 31, 2014.

The Company did not generate revenues during either the three month or nine month period ending September 30, 2015or 2014.  The Company incurred general and administrative expenses of $13,343 during the three month period ended September 30, 2015, as compared to $995 during the three months ended September 30, 2014.  During the nine month period ended September 30, 2015, the Company incurred general and administrative expenses of $29,758 compared to $14,072 during the nine month period ended September 30, 2014.  Such expenses consist primarily of legal and accounting fees as well as taxes and annual fees required to maintain the Company’s corporate status.   

The Company incurred a net loss of $32,596 during the three month period ended September 30, 2015 as compared to a net loss of $188,495 during the three month period ended September 30, 2014.During the nine month period ended September 30, 2015, the Company incurred a net loss of $50,511 compared to a net loss of $203,695 during

the nine month period ended September 30, 2014.  The decrease in net loss in 2015 as compared to 2014 is mainly the result of the loss on extinguishment of debt in the amount of $187,500 which was recorded during the nine months ended September 30, 2014.  

The Company has never had substantial ongoing operations. As a result, since its inception on July 26, 1990, the Company has an accumulated deficit of $457,791.

Liquidity and Capital Resources

Net cash used by operating activities was $18,755 and $16,613 during the nine months ended September 30, 2015 and 2014 respectively.

No cash was provided or used by investing activities during the nine month periods ending September 30, 2015 or 2014.

Net cash provided by financing activities was $100,000 and $16,312 during the nine months ended September 30, 2015 and 2014 respectively.

Since the Company does not generate any revenues from operations, it is dependent on sales of securities, loans, or contributions from its stockholders in order to pay its operating costs. In addition, in the event the Company locates a suitable candidate for potential acquisition, the Company will require additional funds to pay the costs of negotiating and completing the acquisition of such candidate.  The Company has not entered into any agreement or arrangement for the provision of any additional funding and no assurances can be given that such funding will be available to the Company on terms acceptable to it or at all.  

The Company cannot presently foresee the cash requirements of any business opportunity which may ultimately be acquired by the Company.  However, since it is likely that any business it acquires will be involved in active business operations, the Company anticipates that an acquisition will result in increased cash requirements as well as increases in the number of employees of the Company.

Off-Balance Sheet Arrangements

The Company has not entered into any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on its financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures, or capital resources that are material to investors.

Critical Accounting Policies

Due to the lack of current operations and limited business activities, the Company does not have any accounting policies that it believes are critical to facilitate an investor’s understanding of the Company’s financial and operating status.

Recent Accounting Pronouncements

On June 10, 2014, the Financial Accounting Standards Board ("FASB") issued update ASU 2014-10, “Development Stage Entities” (Topic 915). Amongst other things, the amendments in this update removed the definition of development stage entity from Topic 915, thereby removing the distinction between development stage entities and other reporting entities from US GAAP. In addition, the amendments eliminate the requirements for development stage entities to (1) present inception-to-date information on the statements of income, cash flows and shareholders’ equity, (2) label the financial statements as those of a development stage entity; (3) disclose a description of the development stage activities in which the entity is engaged, and (4) disclose in the first year in which the entity is no longer a development stage entity that in prior years it had been in the development stage. The amendments are effective for annual reporting periods beginning after December 31, 2014 and interim reporting periods beginning after December 15, 2015. As such, the Company has not labeled the financial statements as those of a development stage entity and has not presented inception-to-date information on the respective financial statements.

Item 3.  Quantitative and Qualitative Disclosures About Market Risk.

Not Applicable.  The Company is a “smaller reporting company.”

Item 4.Controls and Procedures.

Disclosure Controls and Procedures

Under the supervision and with the participation of our management, including our Chief Executive Officer/Chief Financial Officer, we evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rule 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934 (“the Exchange Act”) as of September 30, 2015, the end of the period covered by this report.  Based upon that evaluation, our Chief Executive Officer/Chief Financial Officer, who is our sole officer and director, concluded that our disclosure controls and procedures as of September 30, 2015 were not effective such that the information required to be disclosed by us in reports filed under the Exchange Act is (i) recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and (ii) accumulated and communicated to our management, including our Chief Executive Officer/Chief Financial Officer, as appropriate to allow timely decisions regarding disclosure.  A controls system cannot provide absolute assurance, however, that the objectives of the controls system are met, and no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within a company have been detected.  

Changes in Internal Control over Financial Reporting

There was no change in our internal control over financial reporting during the quarter ended September 30, 2015 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

In connection with an evaluation of the effectiveness of the Company’s internal control over financial reporting as of September 30, 2015, using the COSO framework (1992), our management, with the participation of our Chief Executive Officer/Chief Financial Officer identified a weakness in the Company’s internal control, which arises from the fact that the Company’s principal executive and principal financial officers are the same person, which does not allow for segregation of duties.  Our management believes the materiality of this weakness is mitigated by the Company’s status as a shell company with no significant assets or liabilities, no business operations and a limited number of transactions each year, and that the weakness does not have a material effect on the accuracy and completeness of our financial reporting and disclosure as included in this report.

Part II---OTHER INFORMATION

Item 1.Legal Proceedings.

The Company is not a party to any material pending legal proceedings and, to the best of its knowledge; its properties are not the subject of any such proceedings.

Item 1A.Risk Factors.

See the risk factors described in Item 1A of the Company’s annual report on Form 10-K for the fiscal year ended December 31, 2014.

Item 2.Unregistered Sales of Equity Securities and Use of Proceeds.

None.

Item 3. Defaults Upon Senior Securities.

Not Applicable.

Item 4. Mine Safety Disclosures.

Not Applicable.

Item 5.Other Information.

None.

Item 6.

Exhibits

The following documents are included as exhibits to this report:

(a)

Exhibits

Exhibit Number	SEC Reference Number	Title of Document	Location
31.1	31	Section 302 Certification of Chief Executive and Chief Financial Officer	This Filing
32.1	32	Section 1350 Certification of Chief Executive and Chief Financial Officer	This Filing
101.INS**		XBRL Instance Document	This Filing
101.SCH**		XBRL Taxonomy Extension Schema	This Filing
101.CAL**		XBRL Taxonomy Extension Calculation Linkbase	This Filing
101.DEF**		XBRL Taxonomy Extension Definition Linkbase	This Filing
101.LAB**		XBRL Taxonomy Extension Label Linkbase	This Filing
101.PRE**		XBRL Taxonomy Extension Presentation Linkbase	This Filing

**XBRL information is furnished and not filed for purposes of Sections 11 and 12 of the Securities Act of 1933 and Section 18 of the Securities Exchange Act of 1934, and is not subject to liability under those sections, is not part of any registration statement or prospectus to which it relates and is not incorporated or deemed to be incorporated by reference into any registration statement, prospectus or other document.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Bioethics, Ltd.
Date:  November 10, 2015	By  /s/ Mark A. Scharmann
	Mark A. Scharmann
	President, Chief Executive Officer and
	Chief Financial Officer
	(Principal Executive and Financial Officer)

EX-31

Exhibit 31.1

I, Mark A. Scharmann, certify that:

1.

I have reviewed this report on Form 10-Q of Bioethics, Ltd;

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.

The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal controls over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f) for the registrant and we have:

a.

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b.

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c.

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d.

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.

The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a.

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b.

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

	Bioethics, Ltd.
Date:  November 10, 2015	By  /s/ Mark A. Scharmann
	Mark A. Scharmann
	President, Chief Executive Officer and
	Chief Financial Officer
	(Principal Executive and Financial Officer)

EX-32

Exhibit 32.1

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Bioethics, Ltd. (the “Company”) on Form 10-Q for the fiscal quarter ended September 30, 2015 as filed with the Securities and Exchange Commission on or about the date hereof (the “Report”), I, Mark A. Scharmann, President, Chief Executive Officer and Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

	Bioethics, Ltd.
Date:  November 10, 2015	By  /s/ Mark A. Scharmann
	Mark A. Scharmann
	President, Chief Executive Officer and
	Chief Financial Officer
	(Principal Executive and Financial Officer)

XML

Note 5 - Going Concern

9 Months Ended

Sep. 30, 2015

Notes

Note 5 - Going Concern

NOTE 5 - GOING CONCERN

The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America, which contemplate continuation of the Company as a going concern.  However, the Company has incurred losses since its inception and has no on-going operations.  These factors raise substantial doubt about the ability of the Company to continue as a going concern.  In this regard, management is proposing to raise any necessary additional funds not provided by operations through loans, additional sales of its common stock or through a possible business combination.  There is no assurance that the Company will be successful in raising this additional capital or in achieving profitable operations.  The financial statements do not include any adjustments that might result from the outcome of these uncertainties.

XML

Note 4 - Convertible Note Payable

9 Months Ended

Sep. 30, 2015

Notes

Note 4 - Convertible Note Payable

NOTE 4 - CONVERTIBLE NOTE PAYABLE

On July 25, 2015, the Company issued a promissory note in the original principal amount of $100,000 to a lender. The Note is due on demand at any time after July 31, 2016 and carries an interest rate of 10% per annum. The Note shall be due and payable in full unless converted partially or in its entirety upon the election of the lender into fully paid and non-assessable shares of common stock of the Company at a conversion rate of $0.25 per share.  The Company recognized a beneficial conversion feature and recorded a debt discount in the amount of $100,000.  This amount is being amortized over the life of the promissory note.  During the three and nine months ended September 30, 2015, the company recorded $16,667 as amortization of debt discount on the condensed statements of operations, resulting in an unamortized debt discount of $83,333 and net convertible note balance of $16,667 at September 30, 2015.  Accrued interest and interest expense as of and for the nine months ended September 30, 2015 totaled $1,836.

XML

Condensed Balance Sheets - USD ($)	Sep. 30, 2015	Dec. 31, 2014
CURRENT ASSETS
Cash and cash equivalents	$ 92,879	$ 11,634
Prepaid expenses	1,875	7,500
Total Current Assets	94,754	19,134
TOTAL ASSETS	94,754	19,134
CURRENT LIABILITIES
Accounts payable	6,128
Accrued interest	1,836
Accrued interest - related party	1,500
Note payable - related party	25,000	25,000
Convertible note payable (net of discount of $83,333 and $-0-, respectively)	16,667
Total Current Liabilities	51,131	25,000
TOTAL LIABILITIES	51,131	25,000
STOCKHOLDERS' EQUITY (DEFICIT)
Common stock, $0.001 par value; 150,000,000 shares authorized, 116,000,000 shares issued and outstanding	116,000	116,000
Additional paid-in capital	385,414	285,414
Accumulated deficit	(457,791)	(407,280)
Total Stockholders' Equity (Deficit)	43,623	(5,866)
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)	$ 94,754	$ 19,134

XML

Note 2 - Stockholders' Equity (deficit)

9 Months Ended

Sep. 30, 2015

Notes

Note 2 - Stockholders' Equity (deficit)

NOTE 2 - STOCKHOLDERS’ EQUITY (DEFICIT)

Common Stock - In July 1990, in connection with its organization, the Company issued 1,000,000 shares of its previously authorized but unissued common stock.  Total proceeds from the sale of stock amounted to $1,000 (or $.001 per share).

In May 1998, the Company issued 10,000,000 shares of its previously authorized but unissued common stock.  Total proceeds from the sale of stock amounted to $40,000 (or $.004 per share).  The issuance of common stock resulted in a change in control of the Company.

In June 2014, the Company issued 105,000,000 shares of its previously authorized but unissued common stock for satisfaction of debts in the amount of $105,000 (see NOTE 3). The best-efforts Enterprise value of the shares issued was determined by management to be $292,500 (or $.003 per share). The excess of the fair value of the stock issued over the value of the debt settled of $187,500 has been recorded as a loss on extinguishment of debt.  The transaction resulted in a change in control of the Company, as well as a restatement of the September 30, 2014 comparative financial statements as illustrated in NOTE 9.

As discussed in NOTE 4, the Company recorded a debt discount totaling $100,000 in connection with a convertible note payable issued during the three months ended September 30, 2015.  This resulted in a corresponding increase of $100,000 to additional paid-in capital.

XML

Note 3 Related Party Transactions

9 Months Ended

Sep. 30, 2015

Notes

Note 3 Related Party Transactions

NOTE 3 RELATED PARTY TRANSACTIONS

Management Compensation - During the three and nine months ended September 30, 2015 and 2014, the Company did not pay any compensation to its officers and directors.

Office Space - The Company has not had a need to rent office space.  An officer/shareholder of the Company is allowing the Company to use his home as a mailing address, as needed, at no expense to the Company.

Notes Payable - Between January 2010 and March 2014, the Company borrowed $91,000 from a minority stockholder of the Company pursuant to unsecured promissory notes, which were due on demand and accrued interest at 6% per annum. In June 2014, the principal amount of $91,000, along with accrued interest of $14,000, was purchased by the Company’s then-sole officer and director and settled via the issuance of 105,000,000 shares of common stock of the Company.  This resulted in a change of control, as the former officer and director now owns 90.5% of the Company’s issued and outstanding stock.  In December 2014, the Company borrowed $25,000 from this majority shareholder pursuant to an unsecured promissory note, which is due on demand and accrues interest at 12% per annum, or $750 per quarter.  The note has accrued $2,250 in interest since its inception, of which $1,500 remains payable at September 30, 2015.

XML

Condensed Statements of Operations - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
OPERATING EXPENSES
General and administrative	$ 13,343	$ 995	$ 29,758	$ 14,072
Total Operating Expenses	13,343	995	29,758	14,072
LOSS FROM OPERATIONS	(13,343)	(995)	(29,758)	(14,072)
OTHER INCOME (EXPENSES)
Loss on extinguishment of debt		(187,500)		187,500
Interest expense	(19,253)		(20,753)	(2,123)
Total Other Income (Expenses)	(19,253)	(187,500)	(20,753)	(189,623)
NET LOSS BEFORE INCOME TAXES	(32,596)	(188,495)	(50,511)	(203,695)
NET INCOME (LOSS)	$ (32,596)	$ (188,495)	$ (50,511)	$ (203,695)
BASIC AND DILUTED LOSS PER SHARE	$ (0.00)	$ (0.00)	$ (0.00)	$ (0.00)
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING	116,000,000	116,000,000	116,000,000	81,000,000

XML

Document and Entity Information - USD ($)	9 Months Ended
	Sep. 30, 2015	Jun. 30, 2015
Document and Entity Information:
Entity Registrant Name	BIOETHICS LTD
Document Type	10-Q
Document Period End Date	Sep. 30, 2015
Trading Symbol	bioe
Amendment Flag	false
Entity Central Index Key	0000894560
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding	116,000,000
Entity Public Float		$ 116,000,000
Entity Filer Category	Smaller Reporting Company
Entity Current Reporting Status	No
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q3

XML

Statements of Cash Flows - USD ($)	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (50,511)	$ (203,695)
Adjustments to reconcile net loss to net cash used by operating activities:
Amortization of debt discounts	16,667
Loss on extinguishment of debt		187,500
Changes in operating assets and liabilities:
Prepaid expenses	5,625	(380)
Accounts payable	6,128	(2,161)
Accrued interest	1,836
Accrued interest - related party	1,500	2,123
Net Cash Used by Operating Activities	(18,755)	(16,613)
CASH FLOWS FROM FINANCING ACTIVITIES
Capital contribution		5,137
Proceeds from notes payable	100,000	11,175
Net Cash Provided by Financing Activities	100,000	16,312
INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	81,245	(301)
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD	11,634	359
CASH AND CASH EQUIVALENTS AT END OF PERIOD	92,879	58
SUPPLEMENTAL DISCLOSURES:
Cash paid for interest	$ 750
Non-cash financing activity:
Conversion of unsecured promissory notes payable		$ 105,000

XML

Note 8 - Development Stage Operations

9 Months Ended

Sep. 30, 2015

Notes

Note 8 - Development Stage Operations

Note 8 – DEVELOPMENT STAGE OPERATIONS

On June 10, 2014, the Financial Accounting Standards Board ("FASB") issued update ASU 2014-10, “Development Stage Entities” (Topic 915).   Amongst other things, the amendments in this update removed the definition of development stage entity from Topic 915, thereby removing the distinction between development stage entities and other reporting entities from US GAAP.  In addition, the amendments eliminate the requirements for development stage entities to (1) present inception-to-date information on the statements of income, cash flows and shareholders’ equity, (2) label the financial statements as those of a development stage entity;  (3) disclose a description of the development stage activities in which the entity is engaged, and (4) disclose in the first year in which the entity is no longer a development stage entity that in prior years it had been in the development stage.  The amendments are effective for annual reporting periods beginning after December 31, 2014 and interim reporting periods beginning after December 15, 2015.  As such, the Company has not labeled the financial statements as those of a development stage entity and has not presented inception-to-date information on the respective financial statements

XML

Note 7 - Subsequent Events

9 Months Ended

Sep. 30, 2015

Notes

Note 7 - Subsequent Events

NOTE 7 – SUBSEQUENT EVENTS

The Company has evaluated subsequent events from the balance sheet date through the date the financial statements were issued and determined there are no additional events to disclose.

XML

Note 9 - Restatement

9 Months Ended

Sep. 30, 2015

Notes

Note 9 - Restatement

NOTE 9 – RESTATEMENT

As detailed in NOTE 2, in June 2014 the Company issued 105,000,000 shares of common stock valued at $292,500 for satisfaction of debts in the amount of $105,000.  The loss on extinguishment of debt resulting from the excess of the fair value of the stock issued over the debt settled of $187,500 (with offsetting entry to additional paid-in capital) was not considered at the time of the transaction, and was not recorded until the December 31, 2014 audit.  Thus, the applicable unaudited September 30, 2014 items have been restated in the accompanying financial statements and footnotes as follows:

	At September 30, 2014
	Amount as
	Originally		Restated
Account	Filed	Adjustment	Amount
Additional paid-in capital	$     97,913	$    187,500	$   285,413
Accumulated deficit	(215,284)	(187,500)	(402,784)
	3 Months Ended September 30, 2014			9 Months Ended September 30, 2014
	Amount as			Amount as
	Originally		Restated	Originally		Restated
Account	Filed	Adjustment	Amount	Filed	Adjustment	Amount
Loss on extinguishment of debt	-	(187,500)	(187,500)	-	(187,500)	(187,500)
Total other income (expense)	-	(187,500)	(187,500)	(2,123)	(187,500)	(189,623)
Net loss	(995)	(187,500)	(188,495)	(16,195)	(187,500)	(203,695)
Net loss per share	$      (0.00)	$       (0.00)	$      (0.00)	$    (0.00)	$       (0.00)	$   (0.00)

XML

Note 1 Summary of Significant Accounting Policies

9 Months Ended

Sep. 30, 2015

Notes

Note 1 Summary of Significant Accounting Policies

NOTE 1 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Organization - Bioethics, Ltd. (“the Company”) was organized under the laws of the State of Nevada on July 26, 1990.  The Company was organized to provide a vehicle for participating in potentially profitable business ventures which may become available through the personal contacts of, and at the complete discretion of, the Company’s officers and directors.  The Company has, at the present time, not paid any dividends and any dividends that may be paid in the future will depend upon the financial requirements of the Company and other relevant factors.

Condensed Financial Statements - The accompanying financial statements have been prepared by the Company without audit.  In the opinion of management, all adjustments (which include only normal recurring adjustments) necessary to present fairly the financial position, results of operations and cash flows at September 30, 2015 and 2014 (restated) and for the three and nine months ended September 30, 2015 and 2014 (restated) have been made.

Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted.  It is suggested that these condensed financial statements be read in conjunction with the financial statements and notes thereto included in the Company’s December 31, 2014 audited financial statements.  The results of operations for the periods ended September 30, 2015 and 2014 (restated) are not necessarily indicative of the operating results for the full year.

XML

Note 6 - Loss Per Share

9 Months Ended

Sep. 30, 2015

Notes

Note 6 - Loss Per Share

NOTE 6 - LOSS PER SHARE

The following data show the amounts used in computing loss per share:

	For the	For the	For the	For the
	Three Months	Three Months	Nine Months	Nine Months
	Ended	Ended	Ended	Ended
	September 30,	September 30,	September 30,	September 30,
	2015	2014	2015	2014
		(Restated)		(Restated)
Loss from continuing operations
applicable to common
stockholders (numerator)	$  (32,596)	$ (188,495)	$(50,511)	(203,695)
Weighted average number of
common shares outstanding
used in loss per share calculation
during the period (denominator)	116,000,000	116,000,000	116,000,000	81,000,000

Dilutive loss per share was not presented; as the Company had no common share equivalents for all periods presented that would affect the computation of diluted loss per share. In addition, the Company has experienced continuing losses, so inclusion of any common share equivalents would result in an anti-dilutive effect.